The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions.
For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three primary areas, the first of which is strongly influenced by the latter two:
- market potential,
- epidemiology (including HIV/AIDS patient trends) and
- the current and emerging technologies in both diagnostics and therapeutics.
This in-depth strategic analysis of the worldwide HIV/AIDS market discusses the technologies available and emerging and discusses realistic and theoretical market potential and detailed epidimiological assessments for various geographic regions (many to the national level), including:
- Sub-Saharan Africa
- North Africa/Middle East
- South/Southeast Asia
- East Asia
- Latin America
- Caribbean
- Eastern Europe/Central Asia
- Western/Central Europe
- North America
- Oceania
The report focuses on the policy aspects of HIV/AIDS, the options presented, the factors associated with strategic market development of HIV/AIDS diagnostics and therapeutics, and prospects for the future. The major strategic market effects of epidemiology, medical technology, and market potential analyses are discussed in detail. The trends in epidemiology and social/political attitudes towards HIV/AIDS, as well as their impacts on developing markets, are selected in conjunction with the growing interest in HIV/AIDS preventive medicine. These are presented to provide the most informative picture of potential market advances in this field.
Market analysis for this report is limited in the sense of projections, market shares, etc. Instead, it considers the various aspects of broad market development and estimates throughout the world. It looks at regions of the globe in terms of their existing theoretic and realist market potential. This is tempered by discussions of where and how these markets may develop and the factors influencing them. This report does not discuss in detail the individual products that may be marketed in each of these countries. Some mention is made of specific product types by way of example, but greater emphasis is placed on the product classes, in their generic sense, and their application to HIV/AIDS per se and its complications. The focus of the report is on the strategic factors associated with existing and future market potentials to provide pharmaceutical and diagnostics companies wishing to enter the field with a “field general’s” perspective.
- Executive Summary
- MARKET POTENTIAL
- Table Estimated Theoretical Global Market Potentials for HIV/AIDS Diagnostics and Therapeutics by Region (10 regions) 2005
- Table Estimated Realistic Global Market Potentials for HIV/AIDS Diagnostics and Therapeutics by Region (10 regions) 2005
- EPIDEMIOLOGY
- Table Global Epidemiology View of HIV/AIDS Incidence, Prevalence, Adult Prevalence, and Deaths by Region 2005
- TECHNOLOGY
- Screening and Diagnosis
- Therapeutics
- SCOPE AND METHODOLOGY
- MARKET POTENTIAL
- HIV/AIDS: Nature and Epidemiology
- HIV/AIDS BASICS
- HIV/AIDS COMPLICATIONS
- Tuberculosis
- Toxoplasmosis
- Cytomegalovirus (CMV)
- Kaposi's sarcoma
- Non-Hodgkin's Lymphoma
- Primary CNS Lymphoma
- Hodgkin's Disease
- Cervical Cancer
- Anal Cancer
- Coinfection with Hepatitis C
- HIV/AIDS EPIDEMIOLOGY
- Table Global Summary of HIV/AIDS Populations Average and Range of Prevalance, Incidence, Deaths 2005
- Table Regional HIV/AIDS Statistic and Features: 2005
- HIV/AIDS IN THE UNITED STATES
- Table Estimated Number of Cases of HIV/AIDS in the United States by Year of Diagnosis, Race/Ethnicity, and Transmission Category 2001-2004
- Table Estimated Number of AIDS Cases in the United States by Age at Diagnosis, Race/Ethnicity, Transmission Category, and Region 2000-2004
- Table Estimated Number of People Living with HIV/AIDS in the U.S. by Age at Diagnosis, Race/Ethnicity, and Transmission Category 2001-2004
- Table Estimated Number of Persons Living with AIDS in the United States by Year, Race/Ethnicity, Transmission Category, and Region 2000-2004
- HIV/AIDS IN WESTERN EUROPE
- Table HIV Diagnoses in Western Europe by Country (22 counties) Number of Diagnoses 2004 or 2003, Rate per Million, and Cumulative Total
- Table Estimated Number of People Living with HIV in Western Europe: by Country (26 countries) 2001 and 2003
- HIV/AIDS IN CENTRAL EUROPE, EASTERN EUROPE AND CENTRAL ASIA
- Table HIV Diagnoses in Central and Eastern Europe and in Central Asia by Country: Number of Diagnoses 2004 or 2003, Rate per Million, and Cumulative Total
- Table Estimated Number of People Living with HIV in Central and Eastern Europe and Central Asia by Country (29 Countries) 2001 and 2003
- HIV/AIDS IN AFRICA
- Table Estimated Number of People Living with HIV in Sub-Saharan Africa by Country (44 Countries) 2001 and 2003
- HIV/AIDS IN LATIN AMERICA AND THE CARIBBEAN
- Table Estimated Number of People Living with HIV in Latin America by Country (20 Countries) 2001 and 2003
- Table Estimated Number of People Living with HIV in the Caribbean by Country (7 Countries) 2001 and 2003
- HIV/AIDS IN INDIA,CHINA AND SOUTH/SOUTHEAST ASIA
- India
- China
- South and Southeast Asia
- Table Estimated Number of People Living with HIV in India, China and South/Southeast Asia by Country (20 Countries Total) 2001 and 2003
- HIV/AIDS in North Africa and the Middle East
- Table Estimated Number of People Living with HIV in North Africa and the Middle East by Country (20 Countries) 2001 and 2003
- Screening and Diagnosis
- SCREENING
- CONFIRMATORY TESTING
- DIAGNOSIS
- Table HIV Screening and Confirmatory Testing Products Approved for Use in the United States as of January 9, 2006
- Table Conditions Attributable to or Complicated by HIV
- Table AIDS: Indicator Conditions
- MONITORING TREATMENT AND PROGNOSIS
- HIV/AIDS: Therapeutics
- DRUG THERAPY
- Binding
- Reverse Transcription
- Table Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Approved by the FDA for Use in HIV/AIDS Treatment (Brand Name, Generic Name, Manufacturer, Approval Date, Time to Approval)
- Table Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Approved by the FDA for Use in HIV/AIDS Treatment (Brand Name, Generic Name, Manufacturer, Approval Date, Time to Approval)
- Integration
- Transcription
- Translation
- Viral Assembly and Maturation
- Table Protease Inhibitors (PIs) Approved by the FDA for Use in HIV/AIDS Treatment (Brand Name, Generic Name, Manufacturer, Approval Date, Time to Approval)
- Table Generic Drugs Used in the Treatment of HIV Infection (Generic Name, Manufacturer, Approval Date, Time to Approval)
- Table Drugs Approved by the FDA for Use in Pediatric HIV/AIDS Treatment (Generic Name, Manufacturer, Adult Approval Date, Pediatric Approval Date)
- Table Drugs Approved by the FDA for Use in the Treatment of HIV/AIDS Complications (Brand Name, Generic Name[s], Use, Manufacturer, Approval Date)
- MICROBICIDES
- CHEMOKINE THERAPEUTICS
- GENES AND HIV/AIDS
- HIV/AIDS VACCINES
- Therapeutic Vaccines
- Preventive Vaccines
- DRUG THERAPY
- Strategic Assessment of HIV/AIDS
- MARKET POTENTIAL
- Table Estimated Theoretical Global Market Potentials for HIV/AIDS Diagnostics and Therapeutics by Region (10 regions) 2005
- Table Estimated Realistic Global Market Potentials for HIV/AIDS Diagnostics and Therapeutics by Region (10 regions) 2005
- EPIDEMIOLOGY
- The "Next Wave" Countries
- Table High and Low Estimates of Current and Future HIV/AIDSInfected Adults in the "Next-Wave" Countries 2002 and 2010
- Existing Epidemics-Africa
- The "Next Wave" Countries
- TECHNOLOGY
- MARKET POTENTIAL
- Glossary
- Companies Active in HIV/AIDS Therapeutics and Diagnostics
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook